Journal of Antimicrobial Chemotherapy, Vol 39, 43-49, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy
D Felmingham, MJ Robbins, K Ingley, I Mathias, H Bhogal, A Leakey, GL Ridgway and RN Gruneberg
Trovafloxacin (CP-99,219) was very active against Gram-negative species
examined including Haemophilus influenzae, Moraxella catarrhalis,
Legionella spp., Neisseria spp. and Escherichia coli (MIC90s < or = 0.03
mg/L). In general trovafloxacin was twice as active as ofloxacin but only
half as active as ciprofloxacin against Gram-negative species.
Trovafloxacin was active against Gram-positive organisms, including
Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes and
Enterococcus faecalis (MIC90s < or = 0.25 mg/L). Against these organisms
activity was eight to 16 times greater for trovafloxacin than for either
ofloxacin or ciprofloxacin. In addition, Chlamydia spp., Mycoplasma spp.
and Ureaplasma urealyticum were eight to 16 times more susceptible to
trovafloxacin than to either ofloxacin or ciprofloxacin. These in-vitro
data show that trovafloxacin is a broad-spectrum fluoroquinolone with
greater activity against clinically important Gram- positive species
compared with ofloxacin or ciprofloxacin.
ORIGINAL ARTICLES
In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates
GR MICRO Ltd, London, UK.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  I. S. Barequet, P. Denton, G. J. Osterhout, S. Tuli, and T. P. O'Brien Treatment of Experimental Bacterial Keratitis With Topical Trovafloxacin Arch Ophthalmol, January 1, 2004; 122(1): 65 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Gordon, M. A. Pfaller, R. N. Jones, and the SENTRY Participants Group BMS284756 (formerly T-3811, a des-fluoroquinolone) potency and spectrum tested against over 10 000 bacterial bloodstream infection isolates from the SENTRY antimicrobial surveillance programme (2000) J. Antimicrob. Chemother., May 1, 2002; 49(5): 851 - 855. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Jonas, I. Engels, C. Friedhoff, B. Spitzmuller, F. D. Daschner, and U. Frank Efficacy of moxifloxacin, trovafloxacin, clinafloxacin and levofloxacin against intracellular Legionella pneumophila J. Antimicrob. Chemother., February 1, 2001; 47(2): 147 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Takahata, M. Shimakura, R. Hori, K. Kizawa, Y. Todo, S. Minami, Y. Watanabe, and H. Narita In Vitro and In Vivo Efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae Antimicrob. Agents Chemother., January 1, 2001; 45(1): 312 - 315. [Abstract] [Full Text]
|
|
|
|
|
|
M. D. Cubbon and R. G. Masterton New quinolones--a fresh answer to the pneumococcus J. Antimicrob. Chemother., December 1, 2000; 46(6): 869 - 872. [Full Text] [PDF]
|
|
|
|
|
|
C. M. Bebear, H. Renaudin, A. Charron, D. Gruson, M. Lefrancois, and C. Bebear In Vitro Activity of Trovafloxacin Compared to Those of Five Antimicrobials against Mycoplasmas Including Mycoplasma hominis and Ureaplasma urealyticum Fluoroquinolone-Resistant Isolates That Have Been Genetically Characterized Antimicrob. Agents Chemother., September 1, 2000; 44(9): 2557 - 2560. [Abstract] [Full Text]
|
|
|
|
|
|
S. N. Vostrov, O. V. Kononenko, I. Y. Lubenko, S. H. Zinner, and A. A. Firsov Comparative Pharmacodynamics of Gatifloxacin and Ciprofloxacin in an In Vitro Dynamic Model: Prediction of Equiefficient Doses and the Breakpoints of the Area under the Curve/MIC Ratio Antimicrob. Agents Chemother., April 1, 2000; 44(4): 879 - 884. [Abstract] [Full Text]
|
|
|
|
|
|
C. Thornsberry, M. E. Jones, M. L. Hickey, Y. Mauriz, J. Kahn, and D. F. Sahm Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998 J. Antimicrob. Chemother., December 1, 1999; 44(6): 749 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dedicoat and P. Venkatesan The treatment of Legionnaires' disease J. Antimicrob. Chemother., June 1, 1999; 43(6): 747 - 752. [Full Text] [PDF]
|
|
|
|
|
|
M. Takahata, J. Mitsuyama, Y. Yamashiro, M. Yonezawa, H. Araki, Y. Todo, S. Minami, Y. Watanabe, and H. Narita In Vitro and In Vivo Antimicrobial Activities of T-3811ME, a Novel Des-F(6)-Quinolone Antimicrob. Agents Chemother., May 1, 1999; 43(5): 1077 - 1084. [Abstract] [Full Text]
|
|
|
|
|
|
E. B. Breitschwerdt, M. G. Papich, B. C. Hegarty, B. Gilger, S. I. Hancock, and M. G. Davidson Efficacy of Doxycycline, Azithromycin, or Trovafloxacin for Treatment of Experimental Rocky Mountain Spotted Fever in Dogs Antimicrob. Agents Chemother., April 1, 1999; 43(4): 813 - 821. [Abstract] [Full Text]
|
|